Cargando…
Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Anaplastic Thyroid Carcinoma
Posterior reversible encephalopathy syndrome (PRES) is a rare reversible neurological syndrome that causes subcortical vasogenic brain edema and which is associated with the use of target-specific agents. Lenvatinib is a target-specific agent that was recently approved for inoperable thyroid cancer....
Autores principales: | Osawa, Yoko, Gozawa, Rikako, Koyama, Keisuke, Nakayama, Takeo, Sagoh, Tadashi, Sunaga, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919864/ https://www.ncbi.nlm.nih.gov/pubmed/29225265 http://dx.doi.org/10.2169/internalmedicine.9593-17 |
Ejemplares similares
-
Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017) -
Anaplastic thyroid carcinoma diagnosed after treatment of lenvatinib for papillary thyroid carcinoma
por: Yamazaki, Haruhiko, et al.
Publicado: (2019) -
Posterior Reversible Encephalopathy Syndrome as an Adverse Effect of Lenvatinib in a Patient with Papillary Thyroid Carcinoma: A Case Report
por: Buenaventura, Daisy Carolina, et al.
Publicado: (2023) -
Lenvatinib vs. palliative therapy for stage IVC anaplastic thyroid cancer
por: Iwasaki, Hiroyuki, et al.
Publicado: (2020) -
Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review
por: Chae, Young Kwang, et al.
Publicado: (2018)